Personalis received UKCA marking for its NeXT Personal Dx MRD assay, expanding clinical use across England, Wales, and Scotland. The company partnered with Link Medical Solutions to support commercialization throughout Great Britain, positioning the test for minimal residual disease monitoring using circulating tumor DNA in blood to detect lingering cancer and inform therapy response and recurrence management.